Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2828 for:    Neuroendocrine Neoplasm | Neuroendocrine Tumors
Previous Study | Return to List | Next Study

Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences (NETMRI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03948841
Recruitment Status : Completed
First Posted : May 14, 2019
Last Update Posted : May 14, 2019
Sponsor:
Information provided by (Responsible Party):
CHU de Reims

Brief Summary:

The aim of our study is to assess variability of measurements of liver metastases from neuroendocrine tumors (NET) on different magnetic resonance imaging (MRI) sequences.

In this institutional review board-approved retrospective study from January 2011 to December 2012, all liver MRIs performed at our department in patients with proven liver metastases from NETs and with at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST 1.1) were included.


Condition or disease Intervention/treatment
Neuroendocrine Tumors Other: magnetic resonance imaging

Detailed Description:

The aim of our study is to assess variability of measurements of liver metastases from neuroendocrine tumors (NET) on different magnetic resonance imaging (MRI) sequences.

In this institutional review board-approved retrospective study from January 2011 to December 2012, all liver MRIs performed at our department in patients with proven liver metastases from NETs and with at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST 1.1) were included. Up to two lesions were selected by an independent radiologist on T2-weighted images and marked by an arrow. Three reviewers (attending radiologist R1, fellow R2, senior R3) independently obtained long axis measurements of 135 metastases in 30 patients, on T2, diffusion-weighted imaging (DWI) with three b values (50, 400, 800), arterial, portal and late phases after gadolinium ), and during two distant separate sessions. Intraclass correlation coefficients and Bland-Altman plots were used to assess intra-and interobserver variability.


Layout table for study information
Study Type : Observational
Actual Enrollment : 41 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences
Actual Study Start Date : January 1, 2011
Actual Primary Completion Date : December 1, 2012
Actual Study Completion Date : September 1, 2016

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Neuroendocrine tumor
Patients with liver metastasis from neuroendocrine tumor
Other: magnetic resonance imaging



Primary Outcome Measures :
  1. variability of measurements of liver metastases from neuroendocrine tumors (NET) on different magnetic resonance imaging (MRI) sequences. [ Time Frame: Day 0 ]
    calculation of intraclass correlation coefficient



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with liver metastasis from neuroendocrine tumor with a magnetic resonance imaging in Reims university hospital.
Criteria

inclusion criteria :

  • Patients with liver metastasis from neuroendocrine tumor
  • Patients with a magnetic resonance imaging in Reims university hospital
  • Patients with at least one measurable lesion according to Response evaluation criteria in solid tumors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03948841


Locations
Layout table for location information
France
Damien JOLLY
Reims, France
Sponsors and Collaborators
CHU de Reims

Publications:
Layout table for additonal information
Responsible Party: CHU de Reims
ClinicalTrials.gov Identifier: NCT03948841     History of Changes
Other Study ID Numbers: 2018Ao006
First Posted: May 14, 2019    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CHU de Reims:
Neuroendocrine tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neoplasms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue